December 1, 2020

The Niche

Knoepfler lab stem cell blog

spinal cord injury

3 min read

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung cancer treatment based on stem cells that sounds quite intriguing. To learn more about this exciting news I interviewed Jane Lebkowski, President of Research and Development at Asterias. 1. …Read More

3 min read

The severe spinal cord injury sustained by Jockey Michael Martinez and the possibility (not realized) that he might be enrolled in Geron’s hESC-based spinal cord regenerative medicine trial, have drawn recent attention to spinal cord injury. Christopher and Dana Reeve (see foundation here) as well as Don C. Reed (see site here) were instrumental in bringing attention to the significance of this injury and the importance of research to help patients with spinal cord injuries. More than 1 million Americans are living with spinal cord …Read More